Levodopa/Carbidopa/Entacapon Heumann

Levodopa, Carbidopa, and Entacapone, the active ingredients in Levodopa/Carbidopa/Entacapon Heumann, are a dopamine precursor combined with a COMT inhibitor presented as an oral tablet for oral use. It is employed to manage the motor symptoms of Parkinson's disease in adult patients.

GNH USA supplies Levodopa/Carbidopa/Entacapon Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and comprehensive regulatory support throughout the supply chain.

Levodopa/Carbidopa/Entacapone is used in the management of Parkinson's disease and related motor complications. - Parkinson's disease (adjunct to levodopa): enhances central dopamine availability and prolongs levodopa effect, improving motor control. - Motor fluctuations in Parkinson's disease: reduces OFF periods and increases ON time without troublesome dyskinesia. - Wearing‑off phenomenon in Parkinson's disease: stabilizes dopamine levels to provide more consistent symptom control.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Headache - Insomnia

Serious or Rare Side Effects: - Dyskinesia or involuntary movements - Hallucinations or psychosis - Severe hypotension or syncope - Cardiac arrhythmias - Neuroleptic malignant syndrome - Hepatic dysfunction or elevated liver enzymes

When prescribing Levodopa/Carbidopa/Entacapone, clinicians should observe several precautionary measures to ensure patient safety. - Blood pressure monitoring: watch for orthostatic hypotension, especially during dose initiation or titration. - Liver function assessment: evaluate hepatic enzymes before starting therapy and periodically thereafter. - Renal impairment adjustment: consider dose modification in patients with severe renal dysfunction. - Cardiac disease caution: use carefully in patients with a history of arrhythmias or ischemic heart disease. - Hypersensitivity awareness: discontinue if signs of allergic reaction such as rash, pruritus, or angioedema appear. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Levodopa/Carbidopa/Entacapone can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (dopamine antagonists): may diminish therapeutic effect and worsen Parkinsonism. - Other COMT inhibitors: can lead to excessive levodopa levels.

Moderate Interactions (Monitor Closely): - SSRIs and SNRIs: may increase risk of serotonin syndrome. - Iron or calcium supplements: can reduce levodopa absorption; separate dosing by at least 2 hours. - Antihypertensive agents: additive hypotensive effect; monitor blood pressure. - High‑protein meals: may compete with levodopa transport, reducing its absorption.